RxDoctor Payments Data

Kimberly Itayem

Clinical Nurse Specialist · Cleveland, OHNPI 1013374917

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Organogenesis Inc. at 32.8% of the total. Reporting peaked in 2024 at $1,224 and has fallen 95.9% since, to $51 in 2025.

$1,844in general payments, 2019–2025

Across 33 payments — averaging $55.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$605
  • Penumbra, Inc.$278
  • Kerecis Limited$184
  • Convatec Inc.$180
  • Medtronic$152
  • Novo Nordisk$125
  • plus $320 from 6 others

What the payments were for

  • Food & beverage$1,844100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,844 in reported general payments places this provider in the 80th percentile of 97 clinical nurse specialist providers in Ohio.

See all clinical nurse specialist providers in Ohio

Medicare billing

Part B allowed, 2024
$76,038
Medicare patients
189
Services billed
653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Midodrine Hcl14$1,814
Famotidine13$421

Paid to pharmacies, not to this prescriber.

Other clinical nurse specialist in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →